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Abstract: 
Understanding the effect of surfactant properties is critical when designing vesicular delivery systems. This 
review evaluates previous studies to explain the influence of surfactant properties on the behaviour of lipid 
vesicular systems, specifically their size, charge, stability, entrapment efficiency (EE), pharmacokinetics, and 
pharmacodynamics. Generally, the size of vesicles decreases by increasing the surfactant concentration, 
carbon chain length, the hydrophilicity of the surfactant head group, and the hydrophilic-lipophilic balance 
(HLB). Increasing surfactant concentration can also lead to an increase in charge, which in turn reduces vesicle 
aggregation and enhances the stability of the system. The vesicles entrapment efficiency not only depends on 
the surfactant properties but also on the encapsulated drug. For example, the encapsulation of a lipophilic 
drug could be enhanced by using a surfactant with a low HLB value. Moreover, the membrane permeability of 
vesicles depends on the surfaĐtaŶt’s ĐarďoŶ ĐhaiŶ leŶgth and transition temperature (Tc). Additionally, 
surfactants have a clear influence on pharmacokinetics and pharmacodynamics such as sustaining drug release, 
enhancing the circulation time of vesicles, improving targeting and cellular uptake.  
Keywords: lipid based vesicles, Surfactant, Liposome, Transfersome, Hydrophilic- lipophilic balance, Entrapment efficiency, 
Zeta potential, and Stability. 
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1. Introduction: 
In recent years, the development of better delivery systems for drugs with some undesirable properties has gained 
much interest. Improving patient compliance is one of the main drivers for research through achieving a good 
therapeutic profile and reducing unwanted side effects. Substantial attempts have been made to alter 
pharmacokinetic and pharmacodynamic properties such as solubility, permeability, release profile and targeting 1,2. 
They are generally achieved by designing delivery systems such as particulates, polymeric micro/nano spheres, and 
vesicular systems 1,3,4. Vesicular systems usually consist of amphipathic lipids which are self-assembled in aqueous 
media to form one or multi bilayers enclosing a hydrophilic core 5. They are employed as a carrier for both 
hydrophilic and lipophilic active pharmaceutical ingredients (APIs). Hydrophilic drugs are usually encapsulated in the 
aqueous core or adsorbed on the surface of polar head part of the lipid, whereas the lipophilic drugs are 
encapsulated between the concentric bilayer (lipid tails form a suitable lipophilic environment) 6,7 (Figure 1, A). Lipid 
based vesicular systems may be classified depending on many factors such as their constituents, size and number of 
bilayers, which accumulatively affect the final vesicle properties in several ways 8,9. Table 1 summarizes the main 
vesicular systems that are employed for drug delivery.   
Surfactants are found in many therapeutic and cosmetic compounds and were usually considered as penetration 
enhancers 10. However, surfactants are used in the pharmaceutical industry for their ability to solubilise poorly 
soluble drugs, to improve the elasticity of the delivery system and to aid drug delivery across biological membranes 
such as the skin or blood brain barrier11-14. Many researchers have also tried to modify delivery systems (e.g. 
polymeric-nanoparticles) using several surfactants to achieve better properties such as enhanced cellular uptake 13. 
The effect of surfactant molecular structure on their aggregation, adsorption at interfaces and cellular uptake have 
been extensively reported in the literature 13,15-17.  In order to enhance lipid-based vesicular system properties, a new 
generation of liposomes were developed to be flexible and ultra-deformable (Figure 1,B). Alterations to the 
conventional liposome composition were reported, since surfactants were incorporated into their structure as well 
as the lipid component (Table 1). Niosomes, as an example of the mew generation of liposomes, were developed 
using non-ionic surfactants in combination with cholesterol and, although they still bear the same characteristics as 
liposomes, were proven to be more permeable and stable 18,19. As another example transfersomes were considered a 
new generation of liposome with a high deformability, which allows them to squeeze easily through biological 
barriers 20. The presence of surfactants in the composition of lipid-based vesicular systems has been stated as the 
reason for the improvement in many properties such as the entrapment efficiency (EE), stability and permeability 21,22. 
However, the consequence of surfactant presence in the vesicles composition may vary as the properties of the surfactant itself 
change. The aim of this review is to highlight the numerous studies carried out to date and to summarize our current 
understanding of how surfactant properties influence the behaviour of vesicle drug delivery systems. 
Table 1 summary of the main lipid based vesicular systems, with their main constituents, distinctive properties and disadvantages  
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2. Surfactants:  
Surfactants, also referred to as surface-active agents or edge activators, are amphipathic molecules and composed 
mainly of two main moieties; the polar hydrophilic part, which is attached to the non-polar lipophilic part 38,39. The 
lipophilic part is usually a straight or branched hydrocarbon chain (tail) consists of eight to eighteen carbon atoms 
(Figure 1, C and D) 40. At low concentrations surfactants exist as monomers, and usually in aqueous medium they 
adsorb on the interfacial surfaces (solution- air interface) and consequently they displace some surface molecules 
and reduce the intermolecular forces, thus lowering the surface tension 41,42. However, above a certain concentration 
(critical micelle concentration (CMC)) they aggregate and form micelles (Figure 1 E and F). The CMC value for each 
surfactant may vary as it depends on the method of determination and other factors such as surface tension, 
viscosity, temperature and conductivity 43,44 . Additionally, many studies reported that CMC is not a precise value, but 
represents a range of concentrations over which the self-assembly of surfactant molecules to form micelles are 
induced 45.  It was also reported that increasing the temperature of the system could cause a reduction in the CMC 
value, which was explained by the destruction of the hydrogen bonds that usually form between the hydrophilic 
groups of surfactants and the water molecules 46-48.  However, surfactants form micelles due to the hydrophobic 
effect, and they could adopt several arrangements 49,50. In aqueous medium, the hydrophilic heads face the aqueous 
surroundings and the lipophilic tails directed toward the non-aqueous medium. However, in a non-polar medium, 
they work similarly but the micelles form in an opposite arrangements where the polar groups face each other and 
the tails project out towards the non-aqueous medium 42 (Figure 1 E and F).  
 
Figure 1. A) The dispersion of drug molecules within the lipid based vesicles, B) comparison between conventional liposome on right half 
and transfersome (elastic liposome) left side, C) surfactant monomer with one tail, D) surfactant monomer with two hydrocarbon tail, E) 
micelle (surfactant assembly) in aqueous medium, F) micelles in non-aqueous medium. 
 
2.1. Classification 
Surfactants may be classified depending on either their molecular weight or their hydrophilic-lipophilic balance 
(HLB) 51 (Figure 2). Moreover, they are further categorised into several sub-groups based on the properties such as 
charge of the hydrophilic head group 51. 
 
Figure 2. Illustrated diagram of surfactant classification based on molecular weight and hydrophilic lipophilic balance.  
 
2.1.1. Classification based on Molecular weight 
A. Low molecular weight surfactants:  
There are four major types of low molecular weight surfactants where the classification depends on the nature of 
the hydrophilic parts. Anionic surfactants have negatively charged hydrophilic parts.  They are widely used due to 
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their low cost. Generally, they could be carboxylates (CnH2n+1COO–x), sulphates (CnH2n+1 OSO3-X), sulphonates 
(CnH2n+1 SO3-x), or phosphates (CnH2n+1OPO (OH) O-x) ), where n is the number of carbon atoms (i.e. n= 8-18) 39,51.  
Cationic surfactants have positively charged hydrophilic parts and often a natural fatty acid. Quaternary 
ammonium compounds are the most commonly used cationic surfactants such as alkyl dimethyl benzyl 
ammonium chloride (benzalkonium chloride), which is widely used as a preservative in pharmaceutical 
formulation (i.e. bactericidal) 39,52. Amphoteric surfactants (zwitterionic) contain both cationic and anionic groups 
and their behaviour is dictated by the pH of the medium in which they are dissolved. They act as anionic 
surfactants in alkaline pH due to their acquisition of a negative charge, whereas in acidic medium they gain a 
positive charge and behave like cations. They show good water solubility, improved stability, and better 
compatibility with other surfactants and within different mediums in comparison with the cationic and anionic 
surfactants. Non-ionic surfactants are characterised by the presence of uncharged hydrophilic groups that do not 
dissociate in aqueous solution such as alcohol, ether, ester or amide groups. They contain wide range of classes 
such as alcohol ethoxylate, sorbitan esters ethoxylate, and fatty acid ethoxylates. Additionally, there are 
multihydroxy products such as glycol esters, glycerol esters, glucosides and sucrose esters 39,51,52 (Table 2). 
B. Polymeric surfactants: 
Polymeric surfactants have been developed in the last two decades and can assembled into one or several 
macromolecular structures that have hydrophilic and lipophilic character.  They are now commonly employed due to 
their wide application as stabilizers in emulsion and suspension formulation. Several modifications have been carried 
out on these surfactants to improve their properties and get molecules that are effective in several pH conditions, 
temperature, and media39,51. The number of the hydrophilic and lipophilic groups as well as their distribution along 
the carbon chain is considered to be a distinctive property of the polymeric surfactants. The high structural 
complexity of the polymeric surfactants exhibit several behavioural differences in comparison with low molecular 
weight surfactants 53. Depending on the distribution of the hydrophilic and lipophilic moieties, these polymeric 
surfactants are usually sub-categorised into two main classes; polysoaps and macrosurfactants 54.
2.1.2. Classification depends on HLB 
The hydrophilic-lipophilic balance classification system was first developed by Griffin in the last century, and it is a 
scale that represents the percentage of hydrophilic to lipophilic groups in surfactant molecules 55. HLB is 
subdivided into several categories based on the range of HLB value, each represents a group of surfactants with 
similar behaviour 39,51. Surfactants with HLB values of 3-6 show more lipophilicity and they tend to form water in 
oil (W/O) emulsion, and micelles/vesicles that are more soluble in non-aqueous media. While HLB values of 8-18 
represent oil in water (O/W) emulsifiers or solubilisers, which are more hydrophilic and water-soluble. However, 
surfactants with HLB values between 7-9 are considered as wetting agents and therefore exhibit both properties. 
Sometimes it is possible to use two or more emulsifying agents (surfactants) at once to achieve the desired 
solubilisation effect. For example, mixing tween 80 (i.e. polysorbate with a HLB value of 15) with Span 80 
(sorbitane monooleate, which has a HLB value of 4.3) in different proportions may cover a range of HLB values in 
order to choose better composition to achieve the desired properties 39,52. Therefore, the optimum use of the HLB 
value is to enable the selection of the surfactant composition. 
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Table 2. Chemical structures of the most commonly used non-ionic surfactants. 
 
3. Surfactants in lipid- based vesicles:  
The uses of surfactants in lipid-based vesicles has progressed over the last few decades 56. Some studies have 
focused on using surfactants from one group e.g. studying the non- ionic surfactants in case of niosomes 57, 
whereas others have investigated the effects of using several surfactants with different characteristics on vesicle 
properties. Additionally, most studies have aimed to maximise the effect of the chosen surfactant in order to 
optimise the formation of the lipid vesicles to achieve the desired size, drug loading and physiochemical 
properties.  
3.1. Surfactant effects on the size and polydispersity index (PDI): 
The presence of surfactants in lipid-based vesicle systems has a noticeable effect on their size. In 2016, Singh et al 
studied the role of surfactant in the formulation of elastic liposomes for the transdermal delivery of the opioid 
analgesic tramadol. The effect of several surfactant (i.e. span 80, tween 80, and sodium deoxycholate) was 
investigated in liposome formulations, where an indirect relationship was observed between liposomes vesicle 
size and surfactant concentration 58. It was suggested that the higher surfactant concentration covered the 
surfaces of the liposomes and therefore prevent them from aggregation 58,59. A small polydispersity index was also 
reported with the higher surfactant concentration and the consistent size distribution was thought to be an 
important factor in reducing interfacial tension and producing a homogeneous emulsion 60. The same three 
surfactants were also used by Jain et al to prepare transfersomes and no significant differences in vesicle size was 
expected, as a result of the homogenization method (through polycarbonated membrane)  used during the 
preparation of the formulations 29,61. However, a reduction in vesicle size was noted when higher surfactant 
concentrations were used, it might be attributed to the fact that surfactant with more than 15% induce micelle 
formation rather than vesicle formation 29. A similar study of the influence of several surfactants on elastic 
liposome properties was carried out by Barbosa et al. 62. They investigated the incorporation of the non-ionic 
surfactants that have either one hydrophobic chain (such as octaethylene glycol laurate (PEG8L), polyoxyethylene 
glycol-4-laurate (PEG4L), and pentaethylene glycol monododecyl ether (C12E5)) or two hydrophobic chains (such 
as polyoxyethylene glycol-8-dilaurate (PEG8DL), and polyoxyethylene glycol-4-dilaurate (PEG4DL)). The study 
revealed similar results, exhibiting higher surfactant concentration lead to the formation of smaller vesicles 62. 
Additionally, surfactants with two hydrophobic chains exhibited better and homogeneous PDI in comparison to 
those with one carbon chain, which could be explained by their better capability to anchor within the lipid bilayer 
62-64. However, not only does the number of the hydrophobic chains affect the vesicle size, but also the length of 
the carbon chain of the surfactant. Duangjit et al. studied the effect of carbon chain length and content of the 
surfactant on meloxicam loaded liposomes 65. The size of the obtained liposomes decreased as the length of 
carbon chain of the surfactant increased from C4 to C16 65. This was attributed to the rise of the surfactant 
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hydrophobicity as its carbon chain length increase, which in turn led to improve the solubility of the surfactant 
molecules within the lipid bilayer 65,66.  
Moreover, a reduction in vesicle size was also reported to be influenced by the hydrophilicity of the head group of 
the surfactant, which was thought to be due to the shortness of the hydrophobic  backbone in comparison to the 
hydrophilic head group, which was asparagine grafts in that case 65,67. Similar results were achieved during 
Ŷiosoŵes loadiŶg ǁith a β-carotene as a model of lipophilic moiety, with the more hydrophilic surfactant ( higher 
HLB value) producing smaller vesicles 33. In contrast, the size of elastic transfersomes optimized with several 
surfactants for the transdermal delivery of pentoxifylline increased as the HLB of the surfactants increased. The 
surfactants were ranked as they formed larger transfersomes in the following order Span 80 < Span 20 < Tween 21 
< Tween 20 61. Similar ranking of several Spans on the niosomes size were obtained, since the size of the vesicles 
increased as the HLB progressively increased, Span 20 (HLB= 8.6) showed larger niosomes size, after that the size 
gradually decreased with Span 40 (HLB= 6.7), Span 60 (4.7) and  Span 80 (HLB= 4.3) 68. This could be due the effect 
of the surface free energy, which might decrease as the hydrophobicity increases 69. 
Some researchers have investigated the effect of the lipid type on vesicle size. The inclusion of some lipids, for 
example, an anionic lipid such as dicetylphosphate (DCP) with Span 20-based niosomes reduced vesicle size. The 
reduction was explained by the increased the curvature of the bilayer caused by the electrostatic repulsion 
between the ionized head group of both the lipid (DCP) and the surfactant 70.  
It has been also suggested that the lipid to surfactant ratio can effect vesicle size. Using cholesterol at higher 
concentrations than usually specified was observed to increase niosomes size 71. Parallel results have been 
obtained by many studies, where the incorporation of cholesterol in niosomes or liposomes at higher 
concentration than the surfactant lead to increase the vesicle size. It was suggested that the competition between 
cholesterol and surfactant to keep their place in the lipid bilayer may increase the size of vesicle 70-73. 
In summary, the inclusion of surfactants within lipid based vesicles has an obvious effect on vesicle size and many 
factors need to be considered when a surfactant is incorporated into the formulation. Parameters such as 
surfactant concentration, number of carbon chains, carbon chain length, and the hydrophilicity of the head groups 
have an inverse effect on vesicle size. While the competition of other moieties with the surfactant molecules 
during the arrangement of the lipid bilayer clearly showed an increase in lipid vesicle size. 
3.2. Surfactant effects on entrapment efficiency: 
Achieving a good EE is considered to be the main goal during the development of any vesicular delivery system. 
Many researches have tried to incorporate surfactants into lipid- based vesicles in order to improve the 
encapsulation of both hydrophobic and hydrophilic drugs as well as reduce drug leakage in liposome formulations 
33,66,67. Although many attempts have been carried out to investigate surfactants effects on improving the EE, 
there is still no definitive proof that specific surfactant properties could lead to certain entrapment. It may entail 
many surfactant properties, such as the type and concentration, that could have an effect on the EE of a certain 
drug within a certain lipid composition 71. General trends could be observed from a set of surfactant properties on 
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a hydrophilic drug entrapment, but that effect could be totally different when a hydrophobic drug is encapsulated. 
The effect of various parameters on the EE are discussed in more details in the following sections. 
3.2.1. Surfactant concentration 
Many researchers have studied the effect of surfactant concentration on vesicle’s EE and it has been commonly 
reported that higher surfactant concentration reduce the EE. This effect has been explained by the possible 
formation of micelles when the surfactant concentration in the bilayer exceeds a critical lamellar/micellar 
transition temperature 29,58,59,74. Furthermore, the permeability of the vesicles membrane might increase due to 
the arrangement of surfactant molecules within the lipid bilayer structure, which could introduce pores within the 
membrane and increase its fluidity 75. Overall, this will prompt entrapped drug leakage 58,76,77. Additionally, it is 
thought that the optimum amount of surfactant depends on the packing density of the phospholipid used and the 
surfactant-phospholipid interaction. When the surfactant concentration increases and it is known to have a high 
tendency to interact with the lipid, this leads to a reduction in entrapment due to competition on the loading 
within the bilayer 72,76,78. For example, transfersomes were prepared and loaded with dexamethasone as a model  
lipophilic drug to evaluate sodium deoxycholate (SDC), Tween 80 and Span 80 as edge activators at five different 
lipid-surfactant ratios (95:5, 90:10, 85:15, 80:20, 75:25) 29. The study revealed that encapsulation efficiency 
decreased as the concentration of the surfactant increased. Transfersomes prepared with SDC showed the lowest 
encapsulation of dexamethasone, as both surfactant and drug possess similar steroidal structure and therefore 
competing each other for their entrapment 29. Similarly, Patel et al. studied the effect of surfactant concentration 
on the entrapment of a lipophilic drug (i.e. curcumin) in lipid-based vesicles and demonstrated that higher 
surfactant concentration lowered the entrapment 76.   
Conversely, other researchers have reported that increasing surfactant concentration will increase the number of 
vesicles formed, which consequently leads to a higher volume of the hydrophobic bilayer domain available to 
house a hydrophobic drug 68,79,80. The impact of surfactant concentration was similar when a low concentration 
was used to prepare Span-based niosomes, a small number of niosomes was obtained, and it was recommended 
that a higher surfactant concentration may improve drug entrapment 77.  
3.2.2. Surfactant structure (carbon chain length, saturation, hydrophilic head group) and transition temperature (Tc) 
Generally it is suggested that by increasing the carbon chain length of the surfactant, the solubility of a lipophilic 
drug in the lipid bilayer should increase and consequently the entrapment efficiency will increase 81,82. On the 
other hand, a point not to forget is that a surfactant with a long carbon chain might compete with a lipophilic drug 
as they assemble themselves within the lipid bilayer, excluding the drug and thus reducing its entrapment 58,83. 
Similar results were observed when niosomes were formulated with different types of Span. All Span surfactants 
have similar head groups and only differ by their hydrophobic chain. Niosomes that were prepared with Span 60 
showed the highest entrapment as it has the longest carbon chain 68,77. In contrast, Span 80 resulted in the lowest 
entrapment efficiency, which was suggested to be related to the unsaturated double bond in its alkyl carbon chain. 
The presence of the double bond within the carbon chain might make it bend and thus would make the niosomes 
bilayer to be more permeable as the packing of the adjacent molecules may not be tight 68,77. Comparable 
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outcomes were observed by El-Laithy et al., when they prepared proniososomes by using several non-ionic 
surfactants such as Tween (80 and 20) , Span (80 and 20) and sugar esters (such as, sucrose stearate, sucrose 
palmitate, sucrose myristate, and sucrose laurate) 79. Although the Tween-based proniosomes showed the lowest 
entrapment efficiency, Tween 80 revealed better encapsulation due to its long carbon chain. Moreover, all sugar 
ester surfactants showed good encapsulation due to their long carbon chains in spite of their high HLB values 79,84.  
Additionally, it was proposed that not only the properties of tail but also the head group of the surfactant might 
influence drug entrapment within vesicles (table 2). The physiochemical properties of Span 60/Tween 60 
niosomes with ellagic acid as a drug were evaluated 85. The study revealed that entrapment efficiency increased 
with Tween 60 niosomes, possibly due the nature of the surfactant head group. The head group of Tween 60 
(polyoxyethylene groups) is larger than the head group of Span 60, which in turn could help solubilize more ellagic 
acid 85. In addition, the formation of hydrogen bonds may be possible between the head group of Tween and the 
phenolic groups and lactone moiety of the ellagic acid 85,86. 
Furthermore, the phase transition temperature (Tc) of the surfactant could be an important factor in explaining 
surfactant effects on EE of lipid-based vesicles. It was reported that the higher the surfactant transition 
temperature, the better their ability to form a more ordered gel structure and a less leaky bilayer, which may 
further improve the entrapment efficiency 79,82,87. While surfactants with a lower Tc could be more liquid in form, 
leading to irregular structural formation and increased fluidity of the vesicles bilayer, that in turn reduces the drug 
entrapment 69,77,88,89. For example, Gupta et al. showed that Span 80 gave the lowest entrapment as it has the 
lowest transition temperature (Tc= -12oC) in comparison to Span 60, 40, and 20 since their transition temperature 
are 53oC, 42oC and16oC respectively 68. These results were consistent with several other studies where the highest 
entrapment of drug was obtained from vesicles prepared using Span with the highest transition temperature 
77,90,91. 
3.2.3. Surfactant HLB value and surfactant physical state 
Evaluating surfactant effects on vesicle entrapment efficiency not only depends on its chemical structure, but also 
requires an understanding of the influence of the hydrophilic-lipophilic balance (HLB). However, the effect of the 
surfactant HLB value on the entrapment still depends on the drug lipophilicity 29,92. Literature suggests that the 
maximum entrapment of a lipophilic drug could be achieved by using a surfactant with a low HLB value 71,93,94. For 
example, Tween 60 was reported to giǀe ďetter eŶĐapsulatioŶ of β-carotene (a model lipophilic drug) when 
compared to Tween 20 since their HLB values are 14.9 and 16.7 respectively 33. Niosomes showed a lower 
tendency to entrap the lipophilic carvedilol, as the HLB value of the surfactant used increased 71,95. Chaudhary et 
al., obtained a higher encapsulation of curcumin from transfersomes prepared using Span 80 (HLB value 4.3) as an 
edge activator compared with Tween 80 (HLB value 15) 58. Similar findings were also exhibited when 
dexamethasone loaded transfersomes were prepared, with both Span 85 and Span 80, with HLB values of 1.8 and 
4.3 respectively, showed higher encapsulation than Tween 80 (HLB 15) and sodium deoxycholate (HLB 16) 29. 
On the other hand, surfactants with high HLB values are thought to give better encapsulation of hydrophilic drugs 
96,97. This was proved by Shaji et al., who prepared piroxicam loaded-transfersomes as sodium deoxycholate based 
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transfersomes, highest encapsulation was obtained in comparison to Tween 80, Span 80 and Span 65 96. 
Surprisingly, contrasting results were obtained when the hydrophilic drug diclofenac sodium was loaded within 
transfersomes using different types of surfactant 92. The surfactants used were ranked according to their ability to 
give the highest encapsulation as: Span 85 > Span 80 > sodium cholate > sodium deoxycholate > Tween 80 92. 
Although Tween 80 did not show higher encapsulation than sodium cholate or sodium deoxycholate, Span based 
transfersomes showed the highest EE regardless of their low HLB values 92.  
Moreover, the physical state of the surfactant could have an effect on vesicles EE 70. Surfactants could be solid, 
such as sodium deoxycholate, gel form such as Span 60 and 40 or a liquid such as Span 80. Gel-type surfactants 
are likely to produce less permeable vesicles than liquid surfactants 70. Several types of surfactant were used in 
the preparation of insulin-loaded niosomes and the presence of the gel-type surfactants such as Span 60 and Span 
40 were found to improve drug entrapment. Whereas niosomes prepared using liquid surfactants such as Span 20 
and Span 80 were thought to be more permeable and showed lower entrapment efficiency 70. 
3.3. Surfactant effects on pharmacokinetics and pharmacodynamics: 
There are many claims that the presence of surfactant could have an effect on the pharmacokinetic and 
pharmacodynamics properties of lipid-based delivery systems, such as enhancing drug release, permeability 
through the route of administration, circulation time and cellular uptake. For example, in surfactant-based 
liposomes, increasing surfactant concentration enhanced the release of the encapsulated drug (ciprofloxacin) 
from the delivery system. However, the amount of ciprofloxacin released was dependant on the type of surfactant 
used and using Tween 80 significantly enhanced release 83. Similar results were obtained in other studies, where 
the use of Tween 80 in liposomal formulations enhanced the flux of drug through the skin 98,99. Although Tween 80 
enhanced the skin permeation of celecoxib-loaded liposomes, it did not show any enhancement of celecoxib 
cellular uptake in comparison to conventional celecoxib liposomes 99. Niosomes were prepared with several types 
of Span for the delivery of the antitumor agent 5-flurouracil (5-FU) and the release rate from formulations 
prepared using Span 40 and Span 60 was slower than those prepared using Span 20 and Span 80 100. This trend 
could be due to the difference in the rigidity and permeability of the formed bilayer, since both Span 40 and Span 
60 have a high Tc and form less permeable bilayer than Span 20 and Span 80.  Additionally, in comparison with 
free drug solution, all surfactant-based vesicles of 5-FU showed higher concentrations of drug in several organs for 
a longer duration that could enhance the possibility of the preferential phagocytic uptake and reduce its 
cytotoxicity100. Also, the pharmacokinetic studies of the 5-FU vesicles reported an increase in the half-life and a 
decrease in the clearance, which in turn maintained a sustained action of 5-FU 100. Similarly, paclitaxel was also 
formulated in niosomes with several surfactants for oral delivery to slow release rate and reduce the toxic side 
effects 93. Moreover, Span 40-based niosomes were more efficient in protecting paclitaxel from the degradation 
by the gastrointestinal enzymes 93. Span 60- based vesicles were also prepared to deliver doxorubicin, showed 
prolonged release, doubled its therapeutic effect (tumoricidal effect) and reduced the drug clearance 101,102.  
Similar results were achieved when several Spans were used to prepare ketoprofen loaded vesicles and Span 60 
was reported to be superior in maintaining the anti-inflammatory effect of ketoprofen for a longer time with 
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slower release rate in comparison to Span 40 103. Confalonieri et al. carried out a comparison between surfactant-
based vesicles and non-niosomal formulations for the delivery of flurbiprufen 104. After IV administration to dairy 
cattle, there was no immunogenical reaction. Furthermore, the surfactant based niosomes showed longer 
circulation time in the vascular space, which could improve the flurbiprufen distribution into the required organs/ 
tissue as well as its short half-life 104. In addition, a high permeation through the skin with an improved 
pharmacological activity and reduced side effects were reported after applying meloxicam-loaded niosomes 
during in vivo animal studies, which were prepared using both Span 60 and ethanol as surfactants 105. A significant 
enhancement in the cellular uptake of gene-loaded niosomes were reported in comparison to a conventional 
liposomal delivery 106. Span 60 and Span 40 were more effective in mediating the cellular uptake of the gene 
(antisense oligonucleotides) during the in vitro study using a COS-7 cell line 106. In summary, surfactants have a 
clear influence on the pharmacokinetic and pharmacodynamic properties of lipid delivery systems, such as 
achieving sustained release, enhancing circulation time, improving targeting and cellular uptake. Nevertheless, the 
impact is not always constant and could alter depending on the properties of the surfactant. 
3.4. Surfactant effects on charge and stability: 
Measuring the electrostatic charge of lipid vesicles is important factor in order to evaluate their surface properties, 
as it might play a crucial role in their stability by either creating repulsive forces or agglomeration 61,96. The net 
charge on the vesicle surfaces was thought to be the combination of both lipid and surfactant charge. However, it 
was  reported that the type of surfactant could greatly affect the zeta potential. For example; between several 
types of surfactant-based transfersomes, cholate-based transfersomes exhibited the highest negative zeta 
potential value 96. Additionally, as the concentration of the surfactant increased, the net charge of the 
transfersomes increased as well 96. This high negative charge was considered to be advantageous as the research 
aimed to prepare transfersomes for transdermal drug delivery 61. Since it was thought to enhance the 
transfersomes permeability and stability due to the repulsive forces between the charge of the vesicles and skin 
surface 61,78. On the other hand, the same research revealed that all Tween-based transfersomes showed positive 
charge, and the greater the hydrophilicity of the Tween (i.e. HLB value) the larger the positive charge on the 
vesicle surfaces 61. Similarly, many studies have reported that as the surfactant concentration increases, the 
vesicles hold a larger zeta potential.  Generally, the high charge could improve vesicles stability by reducing 
aggregation due to the electrostatic repulsions that could occur between them when they bear similar charge on 
their surfaces 59,60,87,107. On the other hand, several studies suggested that increasing the surfactant concentration 
may reduce the physical stability by forming several types of aggregates. These could be elongated vesicles or 
tubules due to the fusion of the spherical vesicles 108. That could be related not only to the surfactant 
concentration but also to the medium pH, since it was reported that at high pH surfactant monomers might have 
looser packing and form more elongated and aggregated vesicles 108.   
Additionally, the surfactant transition temperature was also reported to have an effect on the vesicular system 
stability. It was thought that the surfactant with higher transition temperature could be useful to prepare more 
stable vesicles 68,109,110. Moreover, it was claimed that a surfactant molecular structure such as polyoxyethylene 
alkyl ether could enhance the stability of liposomes. This is because its large hydrophilic group induced a steric 
11 
 
hindrance which impaired liposome aggregation  and improved the stability 111. Similar findings were reported 
when a weak acid type anionic surfactant sodium 3,6,9,12,15-pentaoxaheptacosanoate (AEC4-Na) was used to 
form vesicles. Inhibition of aggregation and the stability were enhanced because of the steric repulsion which was 
induced by the hydrophilic oxyethylene unit of AEC4-Na 112. 
4. Conclusion:  
This review has summarised previous studies from the literature on the influence of surfactants on vesicular 
system properties. Parameters such as surfactant concentration, number of carbon chains, carbon chain length, 
the hydrophilicity of the head groups, the competition of other moieties with the surfactant molecules during the 
arrangement of the lipid bilayer and the HLB values of the surfactant clearly demonstrate an effect on vesicle 
properties such as size, charge and drug entrapment. Apparently, the size of the prepared vesicles decreases by 
increasing the surfactant concentration, its carbon chain length and number, the hydrophilicity of the surfactant 
head group, and the hydrophilic- lipophilic balance (HLB) value. However, the competition that could be raised 
between a surfactant and the lipid could increase the vesicle size. Moreover, the effect of surfactant on the EE not 
only depends on the surfactants properties but also on the nature of encapsulated drug. The encapsulation of a 
lipophilic drug could be enhanced when surfactants with low HLB values are used, whereas surfactants with high 
HLB values enhance the encapsulation of hydrophilic drug. Generally, it has been reported that increasing 
surfactants carbon chain length and using gel like surfactants or surfactants of high transition temperature (Tc) 
could improve the EE. Moreover, unsaturated bonds (in their carbon chain) or using more liquid form surfactants 
may enhance the permeability of the vesicles across membrane; however, it is associated with drug leakage and 
therefore reduced drug entrapment. Higher concentration of surfactant sometimes improves EE due to increasing 
the number of vesicles formed, but conversely other studies showed a reduced drug entrapment due to improved 
membrane permeability. It was also reported that higher surfactant concentration could lead to an increase in the 
charge, which in turn reduces vesicles aggregation and enhances the system stability. Surfactants have a 
significant bearing on the pharmacokinetic and pharmacodynamic properties of lipid-based delivery systems. 
Mainly, surfactants maintain a desirable sustained release, enhance circulation time, targeting and cellular uptake 
of vesicles.   
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Table 3 summary of the main lipid based vesicular systems, with their main constituents, distinctive 
properties and disadvantages  
 
Vesicular system Main constituents Distinctive properties References 
Liposomes 
(Figure 1, B) 
 Natural or synthetic 
Phospholipids (neutral or 
charged).  Cholesterol. 
 Sizes vary between 25-2500 nm  Suitable for both hydrophilic, lipophilic, small 
molecular weight and macromolecular drugs.  Reduced toxicity.  Targeted drug delivery could be achieved. 
 
Disadvantages  Drug leakage.  Expensive.  Low stability.  Low encapsulation of hydrophilic drugs. 
 
Classified as  Multilamellar vesicles (MLV): Onion structure, 
multiple bilayers enclosing many hydrophilic 
compartments.  Large unilamellar vesicles (LUV).  Small unilamellar vesicles (SUV). 
 
6-8 
Niosomes  Non-ionic surfactant 
(uncharged single-chain 
surfactant).  With/or without cholesterol. 
 
 Microscopic lamellar vesicles.  More stable than liposome.  Osmotically active.  Suitable for loading drugs with wide range of 
solubility.  Relatively less expensive than liposome. 
 
Disadvantages  Aggregation.  Fusion.  Drug leakage. 
 
9,10 
Transfersomes/ 
Deformable or 
Ultra-deformable 
liposome 
(Figure 1, B)  
 Edge activator (surfactant).  Natural or synthetic 
Phospholipids (neutral or 
charged). 
 
 High deformability.  Show very high encapsulation for lipophilic drugs.  More stability. 
 
Disadvantages  Difficulty of loading lipophilic drug without 
compromising their deformability.   Expensive to formulate.  Chemically unstable as they are more prone to 
oxidation.  
 
11-13 
 
Ethosomes/Elastic 
vesicles 
 Ethanol (20-45%) as 
permeation enhancer.  Phospholipid. 
 Increase cell membrane lipid fluidity due to the 
presence of ethanol.  Enhanced permeation profile, especially for dermal 
application.  Low risk profile or toxicity.  Relatively simple to manufacture. 
 
14-18 
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Disadvantages  Poor encapsulation/yield.  Possibility of vesicles disruption. 
  
Pro-vesicular 
system 
(Proliposomes/pro
niosomes)  
 Water-soluble porous carrier 
(solid particles).  In addition to the same 
ingredients of the liposome 
or niosome respectively. 
 Mainly to overcome the disadvantages of liposome 
/niosome.  Free flowing dry form that enhance the stability. 
19,20 
Other:  
e.g. 
Herbosomes/Sphin
gosomes/Genosom
es  
 Similar to liposomes, where 
lipid charge, type, or nature 
determine the type of the 
vesicles. 
 Improved stability, e.g. herbosomes as they have 
phytochemical water-soluble particles that form 
stronger bonds with phospholipids in comparison 
with liposomes.  Provide selective passive targeting, e.g. 
sphingosmoes as they contain sphingolipid which 
improves targeting.   Suitable for delivering specific substances such as 
gene, e.g. genosomes.  
 
 1,6,21 
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Table 4. Chemical structures of the most commonly used surfactants. 
Span 80 (C24H44O6) 
 
Span 60 (C24H46O6)  
 
Span 40 (C22H42O6) 
 
Span 65 (C60H114O8)  
 
Tween 80 (C32H60O10) 
 
Tween 60 (C35H68O10) 
 
Tween 20 (C26H50O10) 
 
 
 
Sodium deoxycholate (C24H39NaO4) 
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Figure 1. (a) The dispersion of drug molecules within the lipid-based vesicles, (b) comparison 
between conventional liposome on right half and transfersome (elastic liposome) left 
side, (c) surfactant monomer with one tail, (d) surfactant monomer with 2 hydrocarbon tails, (e) 
micelle (surfactant assembly) in aqueous medium, (f) micelle in nonaqueous 
medium. 
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Figure 2. Illustrated diagram of surfactant classification based on molecular weight and hydrophilic 
lipophilic balance.  
 
